Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction

Oncotarget

Volumn 6, Issue 7, 2015, Pages 4585-4601

  Lamb, Rebecca ^a,b   Harrison, Hannah ^a,b   Smith, Duncan L ^c   Townsend, Paul A ^a   Jackson, Thomas ^a   Ozsvari, Bela ^a,b   Martinez Outschoorn, Ubaldo E ^d   Pestell, Richard G ^d   Howell, Anthony ^a,b   Lisanti, Michael P ^a,b   Sotgia, Federica ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Methionine restriction; Protein synthesis; Puromycin; Rapamycin; Tumor initiating cells

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN; METHIONINE; PROTEIN SYNTHESIS INHIBITOR; PUROMYCIN; RAPAMYCIN; RIBOSOME PROTEIN; S6 KINASE; IMMUNOSUPPRESSIVE AGENT;

AMINO ACID TRANSPORT; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CALORIC RESTRICTION; CANCER STEM CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN RESTRICTION; PROTEIN SYNTHESIS; PROTEOMICS; RNA SYNTHESIS; RNA TRANSLATION; TRANSLATION INITIATION; UPREGULATION; BIOMIMETICS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

BIOMIMETICS; CALORIC RESTRICTION; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASTIC STEM CELLS; PROTEIN BIOSYNTHESIS; PROTEIN SYNTHESIS INHIBITORS; PUROMYCIN; SIROLIMUS; TUMOR CELLS, CULTURED;

EID: 84925002840     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3278     Document Type: Article

References (74)

1. Easwaran H, Tsai HC and Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Molecular cell. 2014; 54(5):716-727.
2. Xin H, Kong Y, Jiang X, Wang K, Qin X, Miao ZH, Zhu Y and Tan W. Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties. Journal of pharmacological sciences. 2013; 122(4):299-304.
3. Duggal R, Minev B, Geissinger U, Wang H, Chen NG, Koka PS and Szalay AA. Biotherapeutic approaches to target cancer stem cells. Journal of stem cells. 2013; 8(3-4):135-149.
4. Sinha N, Mukhopadhyay S, Das DN, Panda PK and Bhutia SK. Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in oral cancer. Oral oncology. 2013; 49(9):854-862.
5. Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M and Stassi G. Therapeutic implications of Cancer Initiating Cells. Expert opinion on biological therapy. 2009; 9(8):1005-1016.
6. Chandler JM and Lagasse E. Cancerous stem cells: deviant stem cells with cancer-causing misbehavior. Stem cell research & therapy. 2010; 1(2):13.
7. Zhang M and Rosen JM. Stem cells in the etiology and treatment of cancer. Current opinion in genetics & development. 2006; 16(1):60-64.
8. Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, Farnie G and Clarke RB. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. Journal of mammary gland biology and neoplasia. 2012; 17(2):111-117.
9. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer research. 2005; 65(13):5506-5511.
10. Moore N and Lyle S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. Journal of oncology. 2011; 2011.
11. Chen MS, Woodward WA, Behbod F, Peddibhotla S, Alfaro MP, Buchholz TA and Rosen JM. Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. Journal of cell science. 2007; 120(Pt 3):468-477.
12. Fillmore CM and Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast cancer research: BCR. 2008; 10(2):R25.
13. Dean M. ABC transporters, drug resistance, and cancer stem cells. Journal of mammary gland biology and neoplasia. 2009; 14(1):3-9.
14. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-760.
15. Phillips TM, McBride WH and Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. Journal of the National Cancer Institute. 2006; 98(24):1777-1785.
16. Jackson TR, Salmina K, Huna A, Inashkina I, Jankevics E, Riekstina U, Kalnina Z, Ivanov A, Townsend PA, Cragg MS and Erenpreisa J. DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells. Cell cycle. 2013; 12(3):430-441.
17. Salmina K, Jankevics E, Huna A, Perminov D, Radovica I, Klymenko T, Ivanov A, Jascenko E, Scherthan H, Cragg M and Erenpreisa J. Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. Experimental cell research. 2010; 316(13):2099-2112.
18. Lagadec C, Vlashi E, Della Donna L, Dekmezian C and Pajonk F. Radiation-induced reprogramming of breast cancer cells. Stem cells. 2012; 30(5):833-844.
19. Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, Thompson EW, Findlay JK and Ahmed N. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Molecular cancer. 2013; 12:24.
20. Nathans D. Puromycin Inhibition of Protein Synthesis: Incorporation of Puromycin into Peptide Chains. Proceedings of the National Academy of Sciences of the United States of America. 1964; 51:585-592.
21. Popovich IG, Anisimov VN, Zabezhinski MA, Semenchenko AV, Tyndyk ML, Yurova MN and Blagosklonny MV. Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. Cancer biology & therapy. 2014; 15(5):586-592.
22. Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, Jasmin JF, Schwarting R, Pestell RG, Blagosklonny MV and Lisanti MP. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol. 2012; 181(1):278-293.
23. Gao B and Roux PP. Translational control by oncogenic signaling pathways. Biochimica et biophysica acta. 2014.
24. Liu H, Zhang W, Wang K, Wang X, Yin F, Li C, Wang C, Zhao B, Zhong C, Zhang J, Peng F, Bi Y, Shen C, Hou X, Zhang D, Liu Y, et al. Methionine and cystine double deprivation stress suppresses glioma proliferation via inducing ROS/autophagy. Toxicology letters. 2014; 232(2):349-355.
25. Sinha R, Cooper TK, Rogers CJ, Sinha I, Turbitt WJ, Calcagnotto A, Perrone CE and Richie JP, Jr. Dietary methionine restriction inhibits prostatic intraepithelial neoplasia in TRAMP mice. The Prostate. 2014; 74(16):1663-1673.
26. Cavuoto P and Fenech MF. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer treatment reviews. 2012; 38(6):726-736.
27. Saleh AD, Simone BA, Palazzo J, Savage JE, Sano Y, Dan T, Jin L, Champ CE, Zhao S, Lim M, Sotgia F, Camphausen K, Pestell RG, Mitchell JB, Lisanti MP and Simone NL. Caloric restriction augments radiation efficacy in breast cancer. Cell cycle. 2013; 12(12):1955-1963.
28. Champ CE, Baserga R, Mishra MV, Jin L, Sotgia F, Lisanti MP, Pestell RG, Dicker AP and Simone NL. Nutrient restriction and radiation therapy for cancer treatment: when less is more. The oncologist. 2013; 18(1):97-103.
29. Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, Eneman J, Crocker A, White J, Tessitore J, Stanley M, Harlow S, Weaver D, Muss H and Plaut K. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast cancer research and treatment. 2009; 114(1):47-62.
30. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Salem AF, Tsirigos A, Lamb R, Sneddon S, Hulit J, Howell A and Lisanti MP. Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. Cell cycle. 2012; 11(23):4390-4401.
31. Francipane MG and Lagasse E. Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget. 2013; 4(11):1948-1962.
32. Lamb R, Harrison H, Hulit J, Smith DL, Lisanti MP and Sotgia F. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. Oncotarget. 2014; 5(22):11029-11037.
33. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC and Li F. The c-Myc target gene network. Seminars in cancer biology. 2006; 16(4):253-264.
34. Gomez-Roman N, Felton-Edkins ZA, Kenneth NS, Goodfellow SJ, Athineos D, Zhang J, Ramsbottom BA, Innes F, Kantidakis T, Kerr ER, Brodie J, Grandori C and White RJ. Activation by c-Myc of transcription by RNA polymerases I, II and III. Biochemical Society symposium. 2006; (73):141-154.
35. Iritani BM and Eisenman RN. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(23):13180-13185.
36. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN and Golub TR. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(7):3260-3265.
37. Greasley PJ, Bonnard C and Amati B. Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis. Nucleic acids research. 2000; 28(2):446-453.
38. Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M, Sanka K, Lee NH, Dang CV and Liu ET. Identification of c-myc responsive genes using rat cDNA microarray. Cancer research. 2000; 60(21):5922-5928.
39. Ruggero D. The role of Myc-induced protein synthesis in cancer. Cancer research. 2009; 69(23):8839-8843.
40. Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, Rao PH and Ruggero D. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008; 456(7224):971-975.
41. Proud CG. Amino acids and mTOR signalling in anabolic function. Biochemical Society transactions. 2007; 35(Pt 5):1187-1190.
42. Proud CG. Cell signaling. mTOR, unleashed. Science. 2007; 318(5852):926-927.
43. Iadevaia V, Wang X, Yao Z, Foster LJ and Proud CG. Evaluation of mTOR-regulated mRNA translation. Methods in molecular biology. 2012; 821:171-185.
44. Wang X and Proud CG. The mTOR pathway in the control of protein synthesis. Physiology. 2006; 21:362-369.
45. Iadevaia V, Zhang Z, Jan E and Proud CG. mTOR signaling regulates the processing of pre-rRNA in human cells. Nucleic acids research. 2012; 40(6):2527-2539.
46. Proud CG. mTOR Signalling in Health and Disease. Biochemical Society transactions. 2011; 39(2):431-436.
47. Averous J and Proud CG. When translation meets transformation: the mTOR story. Oncogene. 2006; 25(48):6423-6435.
48. Vogt PK. PI 3-kinase, mTOR, protein synthesis and cancer. Trends in molecular medicine. 2001; 7(11):482-484.
49. Blume-Jensen P and Hunter T. Oncogenic kinase signalling. Nature. 2001; 411(6835):355-365.
50. Burnett PE, Barrow RK, Cohen NA, Snyder SH and Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(4):1432-1437.
51. Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC, Jr. and Abraham RT. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science. 1997; 277(5322):99-101.
52. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB and Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. The EMBO journal. 1997; 16(12):3693-3704.
53. Shiraki N, Shiraki Y, Tsuyama T, Obata F, Miura M, Nagae G, Aburatani H, Kume K, Endo F and Kume S. Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. Cell metabolism. 2014; 19(5):780-794.
54. Matsuura K, Kodama F, Sugiyama K, Shimizu T, Hagiwara N and Okano T. Elimination of Remaining Undifferentiated Induced Pluripotent Stem Cells in the Process of Human Cardiac Cell Sheet Fabrication Using a Methionine-Free Culture Condition. Tissue engineering Part C, Methods. 2014.
55. Sugimura T, Birnbaum SM, Winitz M and Greenstein JP. Quantitative nutritional studies with water-soluble, chemically defined diets. VIII. The forced feeding of diets each lacking in one essential amino acid. Archives of biochemistry and biophysics. 1959; 81(2):448-455.
56. Breillout F, Hadida F, Echinard-Garin P, Lascaux V and Poupon MF. Decreased rat rhabdomyosarcoma pulmonary metastases in response to a low methionine diet. Anticancer research. 1987; 7(4B):861-867.
57. Guo H, Lishko VK, Herrera H, Groce A, Kubota T and Hoffman RM. Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer research. 1993; 53(23):5676-5679.
58. Theuer RC. Effect of essential amino acid restriction on the growth of female C57BL mice and their implanted BW10232 adenocarcinomas. The Journal of nutrition. 1971; 101(2):223-232.
59. Halpern BC, Clark BR, Hardy DN, Halpern RM and Smith RA. The effect of replacement of methionine by homocystine on survival of malignant and normal adult mammalian cells in culture. Proceedings of the National Academy of Sciences of the United States of America. 1974; 71(4):1133-1136.
60. Mecham JO, Rowitch D, Wallace CD, Stern PH and Hoffman RM. The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochemical and biophysical research communications. 1983; 117(2):429-434.
61. Cao WX, Ou JM, Fei XF, Zhu ZG, Yin HR, Yan M and Lin YZ. Methionine-dependence and combination chemotherapy on human gastric cancer cells in vitro. World journal of gastroenterology: WJG. 2002; 8(2):230-232.
62. Hoshiya Y, Guo H, Kubota T, Inada T, Asanuma F, Yamada Y, Koh J, Kitajima M and Hoffman RM. Human tumors are methionine dependent in vivo. Anticancer research. 1995; 15(3):717-718.
63. Poirson-Bichat F, Goncalves RA, Miccoli L, Dutrillaux B and Poupon MF. Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6(2):643-653.
64. Barja G. The mitochondrial free radical theory of aging. Progress in molecular biology and translational science. 2014; 127:1-27.
65. Sanchez-Roman I and Barja G. Regulation of longevity and oxidative stress by nutritional interventions: role of methionine restriction. Experimental gerontology. 2013; 48(10):1030-1042.
66. Johnson JE and Johnson FB. Methionine restriction activates the retrograde response and confers both stress tolerance and lifespan extension to yeast, mouse and human cells. PloS one. 2014; 9(5):e97729.
67. Koziel R, Ruckenstuhl C, Albertini E, Neuhaus M, Netzberger C, Bust M, Madeo F, Wiesner RJ and Jansen-Durr P. Methionine restriction slows down senescence in human diploid fibroblasts. Aging cell. 2014; 13(6):1038-1048.
68. Brown-Borg HM, Rakoczy SG, Wonderlich JA, Rojanathammanee L, Kopchick JJ, Armstrong V and Raasakka D. Growth hormone signaling is necessary for lifespan extension by dietary methionine. Aging cell. 2014; 13(6):1019-1027.
69. Huang T, Yang B, Zheng J, Li G, Wahlqvist ML and Li D. Cardiovascular disease mortality and cancer incidence in vegetarians: a meta-analysis and systematic review. Annals of nutrition & metabolism. 2012; 60(4):233-240.
70. Orlich MJ, Singh PN, Sabate J, Jaceldo-Siegl K, Fan J, Knutsen S, Beeson WL and Fraser GE. Vegetarian dietary patterns and mortality in Adventist Health Study 2. JAMA internal medicine. 2013; 173(13):1230-1238.
71. Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, Tjonneland A, Nailler L, Boutron-Ruault MC, Clavel-Chapelon F, Krogh V, Palli D, Panico S, Tumino R, Ricceri F, Bergmann MM, Boeing H, et al. Meat consumption and mortality-results from the European Prospective Investigation into Cancer and Nutrition. BMC medicine. 2013; 11:63.
72. McCarty MF, Barroso-Aranda J and Contreras F. The low-methionine content of vegan diets may make methionine restriction feasible as a life extension strategy. Medical hypotheses. 2009; 72(2):125-128.
73. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, et al. Intensive lifestyle changes may affect the progression of prostate cancer. The Journal of urology. 2005; 174(3):1065-1069; discussion 1069-1070.
74. Epner DE, Morrow S, Wilcox M and Houghton JL. Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction. Nutrition and cancer. 2002; 42(2):158-166.